CSIMarket
 


Clovis Oncology inc   (CLVS)
Other Ticker:  
 
 

CLVS's Revenue Growth by Quarter and Year

Clovis Oncology Inc 's Revenue results by quarter and year




CLVS Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 35.97 43.30 39.31
III Quarter September 30.66 37.92 38.77 37.60
II Quarter June 32.14 36.82 39.89 32.98
I Quarter March 34.25 38.05 42.56 33.12
FY   97.05 148.76 164.52 143.01



CLVS Revenue third quarter 2022 Y/Y Growth Comment
Clovis Oncology Inc reported decline in Revenue in the third quarter 2022 by -19.14% to $ 30.66 millions, from the same quarter in 2021.
The contraction in the third quarter 2022 Clovis Oncology Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 1003.68%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 193 other companies have achieved higher Revenue growth. While Clovis Oncology Inc ' s Revenue fall of -19.14% ranks overall at the positon no. 3506 in the third quarter 2022.




CLVS Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -16.93 % 10.15 % 29.52 %
III Quarter September -19.14 % -2.19 % 3.11 % 65.2 %
II Quarter June -12.71 % -7.7 % 20.95 % 38.8 %
I Quarter March -9.99 % -10.6 % 28.5 % 78.83 %
FY   - -9.58 % 15.04 % 49.92 %

Financial Statements
Clovis Oncology Inc 's third quarter 2022 Revenue $ 30.66 millions CLVS's Income Statement
Clovis Oncology Inc 's third quarter 2021 Revenue $ 37.92 millions Quarterly CLVS's Income Statement
New: More CLVS's historic Revenue Growth >>


CLVS Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -5.14 % 11.68 % 4.55 %
III Quarter September -4.6 % 2.99 % -2.81 % 14.01 %
II Quarter June -6.16 % -3.23 % -6.27 % -0.42 %
I Quarter March -4.78 % -12.12 % 8.27 % 9.13 %
FY (Year on Year)   - -9.58 % 15.04 % 49.92 %




Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #194
Healthcare Sector #525
Overall #3506

Revenue Y/Y Growth Statistics
High Average Low
21746.15 % 1003.68 % -100 %
(Dec 31 2017)   (Dec 31 2015)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #194
Healthcare Sector #525
Overall #3506
Revenue Y/Y Growth Statistics
High Average Low
21746.15 % 1003.68 % -100 %
(Dec 31 2017)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Clovis Oncology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
8932.05 % 357.08 % -100 %
(Mar 31 2017)  


CLVS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Clovis Oncology Inc reported fall in Revenue from the second quarter by -4.6% to $ 30.66 millions, from $ 32.14 millions declared in the previous quarter.

Even cyclical influence have not rescue the III. Quarter for the Clovis Oncology inc , Elenore Marino, an industry observer located in Rome said and mentioned that average sequential Revenue growth is at 357.08% for Clovis Oncology Inc .

Within Major Pharmaceutical Preparations industry 183 other companies have achieved higher Revenue quarter on quarter growth. While Clovis Oncology Inc 's Revenue growth quarter on quarter, overall rank is 3166.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #184
Healthcare Sector #478
Overall #3166
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #184
Healthcare Sector #478
Overall #3166
Revenue Q/Q Growth Statistics
High Average Low
8932.05 % 357.08 % -100 %
(Mar 31 2017)  


CLVS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Clovis Oncology Inc realized fall in Revenue from the previous quarter by -4.6% to $ 30.66 millions, from $ 32.14 millions declared in the previous quarter.

Even cyclical circumstance which normally elevate III. Quarter 2022 performance, this simply was not substantial to salvage Major Pharmaceutical Preparations's company III. Quarter performance, Elenore Marino, an industry observer located in Rome said and wrote that average quarter on quarter Revenue growth is at 357.08% for the Major Pharmaceutical Preparations's company.

Within Major Pharmaceutical Preparations industry 183 other companies have achieved higher Revenue quarter on quarter growth. While Clovis Oncology Inc 's Revenue growth quarter on quarter, overall rank is 3166.


Clovis Oncology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 133.02 $ 140.27 $ 144.95 $ 148.76 $ 156.09
Y / Y Revenue Growth (TTM) -14.78 % -10.62 % -9.41 % -9.58 % -2.77 %
Year on Year Revenue Growth Overall Ranking # 2888 # 1844 # 1701 # 2157 # 1726
Seqeuential Revenue Change (TTM) -5.17 % -3.23 % -2.56 % -4.7 % -0.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 2907 # 1897 # 1707 # 3384 # 2520




Cumulative Revenue growth Comment
Clovis Oncology Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -14.78% year on year, at Sep 30 2022 compare to the -10.62% decrease at Jun 30 2022. If the Clovis Oncology Inc 's fiscal year would end at Sep 30 2022, annual Revenue would be $133 millions.

In the Healthcare sector 398 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1844 to 2888.

Revenue TTM Q/Q Growth Statistics
High Average Low
16.22 %
3.55 %
-5.17 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 172
Healthcare Sector # 399
Overall # 2888

Revenue TTM Y/Y Growth Statistics
High Average Low
112.92 %
28.36 %
-14.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 172
Sector # 470
S&P 500 # 2907
Cumulative Revenue growth Comment
Clovis Oncology Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -14.78% year on year, at Sep 30 2022 compare to the -10.62% decrease at Jun 30 2022. If the Clovis Oncology Inc 's fiscal year would end at Sep 30 2022, annual Revenue would be $133 millions.

In the Healthcare sector 398 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1844 to 2888.

Revenue TTM Q/Q Growth Statistics
High Average Low
16.22 %
3.55 %
-5.17 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 172
Healthcare Sector # 399
Overall # 2888

Revenue TTM Y/Y Growth Statistics
High Average Low
112.92 %
28.36 %
-14.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 172
Sector # 470
S&P 500 # 2907




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CLVS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for CLVS's Competitors
Revenue Growth for Clovis Oncology Inc 's Suppliers
Revenue Growth for CLVS's Customers

You may also want to know
CLVS's Annual Growth Rates CLVS's Profitability Ratios CLVS's Asset Turnover Ratio CLVS's Dividend Growth
CLVS's Roe CLVS's Valuation Ratios CLVS's Financial Strength Ratios CLVS's Dividend Payout Ratio
CLVS's Roa CLVS's Inventory Turnover Ratio CLVS's Growth Rates CLVS's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Owens and Minor inc-0.19%$ -0.191 millions
National Research Corporation-0.20%$ -0.201 millions
Livanova Plc-0.24%$ -0.241 millions
Healthcare Services Group Inc -0.27%$ -0.265 millions
Catalent Inc -0.29%$ -0.293 millions
Asensus Surgical Inc -0.31%$ -0.311 millions
Liquidia Corporation-0.43%$ -0.429 millions
Integra Lifesciences Holdings Corp-0.43%$ -0.432 millions
Pediatrix Medical Group Inc -0.62%$ -0.615 millions
China Pharma Holdings Inc -0.64%$ -0.642 millions
Acadia Pharmaceuticals Inc -0.68%$ -0.682 millions
Amgen Inc -0.81%$ -0.805 millions
Syneos Health Inc -0.89%$ -0.891 millions
Hologic Inc-0.93%$ -0.925 millions
Innovage Holding Corp -1.07%$ -1.070 millions
Procyon Corporation-1.20%$ -1.200 millions
Precipio inc -1.38%$ -1.380 millions
Ati Physical Therapy Inc -1.40%$ -1.397 millions
Ocular Therapeutix Inc -1.55%$ -1.547 millions
Alpine Immune Sciences Inc -1.75%$ -1.750 millions
Surgalign Holdings Inc -1.79%$ -1.786 millions
Tenet Healthcare Corp-1.90%$ -1.900 millions
Teleflex Incorporated-1.92%$ -1.923 millions
Novocure Limited-1.95%$ -1.952 millions
Dynatronics Corporation-2.01%$ -2.014 millions
Royalty Pharma Plc-2.10%$ -2.101 millions
National Healthcare Corp-2.13%$ -2.130 millions
Fonar Corporation-2.27%$ -2.271 millions
Psychemedics Corp-2.35%$ -2.353 millions
Escalon Medical Corp -2.63%$ -2.626 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com